Brighter Hope Foundation discusses Genetics, Diagnosis, and Treatment on the DNA Today Podcast

GACI Genetics Diagnosis and Treatment 

In this episode of the DNA Today podcast, experts explore GACI genetics diagnosis and treatment, providing insight into the causes, diagnostic challenges, and emerging therapies for Generalized Arterial Calcification of Infancy (GACI). Hosted by Kira Dineen, the discussion features Christine O’Brien of Brighter Hope Foundation and Dr. Yves Sabbagh of Inozyme Pharma, combining scientific expertise with real-world patient perspectives.

Featured Experts

Kira Dineen, MS, CGC
Host of the DNA Today podcast and certified genetic counselor who helps break down complex genetic concepts.

Christine O’Brien
Co-President of Brighter Hope Foundation and parent advocate. She shares the challenges families face during diagnosis and highlights the importance of patient advocacy and collaboration.

Dr. Yves Sabbagh, PhD
Chief Scientific Officer at Inozyme Pharma. Dr. Sabbagh explains the underlying biology of GACI and ongoing research into targeted treatments.

Understanding GACI Genetics and Causes

GACI is a rare inherited condition involving abnormal calcification in arteries and soft tissues. It is most commonly caused by mutations in the ENPP1 gene, though some cases involve the ABCC6 gene.

These genes regulate levels of pyrophosphate (PPi), a molecule that helps prevent calcium buildup in the body. When PPi levels are reduced, calcium can accumulate in arterial walls, leading to narrowing of blood vessels and serious cardiovascular complications.

Understanding these pathways is essential to advancing GACI genetics diagnosis and treatment and improving outcomes for affected individuals.

Diagnostic Challenges and Genetic Testing

Because GACI is extremely rare, diagnosis can often be delayed. Christine O’Brien discusses the diagnostic odyssey many families experience, which may involve multiple specialists before the condition is identified.

Genetic testing is often necessary to confirm mutations in ENPP1 or ABCC6, helping physicians make an accurate diagnosis and guide care. The episode also highlights programs that may help families access genetic testing and improve early detection.

Emerging Treatments and Future Research

Dr. Sabbagh discusses ongoing research aimed at addressing the underlying causes of ENPP1 deficiency disorders. One investigational therapy being studied is INZ-701, which is designed to help restore balance in the pathways that regulate calcification.

Clinical trials and continued research are working to expand treatment options and improve outcomes for individuals affected by GACI.

Learn more about ongoing research:

Learn More

Brighter Hope Foundation provides educational resources and support for individuals and families affected by:

📌 What is ENPP1 Deficiency? 

📌 What is ABCC6 Deficiency? 

📌 What is ARHR2 Deficiency? 

📌 What is Gaci?

Explore additional resources on our website to learn more about these conditions, available testing options, and ongoing research efforts.